NVCR - NovoCure Ltd

12.23
-0.440   -3.598%

Share volume: 830,149
Last Updated: 04-21-2026
Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$12.67
-0.44
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
44%
Profitability 25%
Dept financing 47%
Liquidity 75%
Performance 55%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.68%
1 Month
3.47%
3 Months
-13.81%
6 Months
-11.76%
1 Year
-25.92%
2 Year
3.38%
Key data
Stock price
$12.23
P/E Ratio 
0.00
DAY RANGE
$12.14 - $12.75
EPS 
-$1.22
52 WEEK RANGE
$9.82 - $20.06
52 WEEK CHANGE
-$31.18
MARKET CAP 
1.448 B
YIELD 
N/A
SHARES OUTSTANDING 
113.794 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-24-2025
BETA 
2.22
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,206,766
AVERAGE 30 VOLUME 
$1,152,199
Company detail
CEO: Asaf Danziger
Region: US
Website: novocure.com
Employees: 1,320
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies
Sector: Manufacturing

NovoCure Limited engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma.

Recent news